SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Sirtex Medical

Status and phase: Terminated; Phase 3; Phase 2

Conditions: Intrahepatic Cholangiocarcinoma

Treatments: Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)

Study type: Interventional

Funder types: Industry

Identifiers

NCT02807181

STX0115

Details and patient eligibility

About

The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients were randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients were randomized to CIS-GEM alone.

Full description

This clinical study was a prospective, multicenter, randomized, controlled study evaluating SIR-Spheres Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy vs. CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic cholangiocarcinoma.

Randomized patients were to be followed until death, withdrawal of consent, or until end of study.

Enrollment: 89 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Willing, able and mentally competent to provide written informed consent.
• Aged 18 years or older.
• Histologically or cytologically confirmed unresectable and non-ablatable intrahepatic cholangiocarcinoma.
• Liver-only or liver predominant intrahepatic cholangiocarcinoma. Patient are permitted to have loco-regional lymph node involvement defined as: portal LN </= to 2 cm and/or para aortic LN </= to 1.5 cm in longest diameter, and/or up to 2 indeterminate lung lesions < 1 cm if these lung lesions are positron emission tomography (PET) negative.
• Chemotherapy naïve. Adjuvant chemotherapy is not permitted.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Adequate hematological function defined as:

Hemoglobin >/= 10g/dL White Blood Cell count (WBC) >/= 3.0 x 10^9/L Absolute neutrophil count (ANC) >/= 1.5 x 10^9/L Platelet count >/= 100,000/mm^3 - Adequate liver function defined as: Total bilirubin </= 30 umol/L (1.75 mg/dL) Albumin >/= 30 g/L

• Adequate renal function defined as: Serum urea and serum creatinine < 1.5 times upper limit of normal (ULN) Creatinine clearance >/= 45 ml/min (calculated with Cockcroft-Gault Equation)

• Life expectancy of at least 3 months without any active treatment
• Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active use an acceptable method of contraception during the study.
• Male patients must be surgically sterile or if sexually active must use an acceptable method of contraception during the study.
• Considered suitable to receive either regimen in the clinical judgement of the treating investigator.

Exclusion criteria

• Patients with only non-measurable lesions in the liver according to RECIST criteria
• Incomplete recovery from previous liver surgery, e.g. unresolved biliary tree obstruction or biliary sepsis or inadequate liver function
• Biliary stent in situ
• Main trunk Portal Vein Thrombosis (PVT)
• Ascites, even if controlled with diuretics. (A minor peri-hepatic rim of ascites detected at imaging is acceptable).
• Mixed hepatocellular carcinoma - intrahepatic cholangiocarcinoma (HCC-ICC) disease
• History of prior malignancy. Exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, recurrent intra-hepatic cholangiocarcinoma post local treatment or any early stage (stage 1) malignancy adequately resected with curative intent at least 5 years prior to study entry
• Suspicion of any bone metastasis/metastases or central nervous system metastasis/metastases on clinical or imaging examination.
• Prior internal or external radiation delivered to the liver.
• Pregnancy; breast feeding.
• Participation within 28 days prior to randomization, in an active part of another clinical study that would compromise any of the endpoints of the study.
• Evidence of ongoing active infection that may affect treatment feasibility or outcome.
• Prior Whipple's procedure.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

89 participants in 2 patient groups

Chemotherapy (Cisplatin-Gemcitabine)

Active Comparator group

Description:

Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.

Treatment:

Drug: Cisplatin-gemcitabine

Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)

Experimental group

Description:

A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.

Treatment:

Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)

Drug: Cisplatin-gemcitabine